FZD9

Summary

FZD9 (frizzled class receptor 9, HGNC:4047) is a protein-coding gene on chromosome 7q11.23, encoding Frizzled-9 (O00144). Receptor for WNT2 that is coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes.

Members of the ‘frizzled’ gene family encode 7-transmembrane domain proteins that are receptors for Wnt signaling proteins. The FZD9 gene is located within the Williams syndrome common deletion region of chromosome 7, and heterozygous deletion of the FZD9 gene may contribute to the Williams syndrome phenotype. FZD9 is expressed predominantly in brain, testis, eye, skeletal muscle, and kidney.

Source: NCBI Gene 8326 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 77 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_003508

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4047
Approved symbol	FZD9
Name	frizzled class receptor 9
Location	7q11.23
Locus type	gene with protein product
Status	Approved
Aliases	FZD3, CD349
Ensembl gene	ENSG00000188763
Ensembl biotype	protein_coding
OMIM	601766
Entrez	8326

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000344575

RefSeq mRNA: 1 — MANE Select: NM_003508 NM_003508

CCDS: CCDS5548

Canonical transcript exons

ENST00000344575 — 1 exons

Exon	Start	End
ENSE00001387101	73433778	73436120

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 87.29.

FANTOM5 (CAGE): breadth broad, TPM avg 2.2319 / max 164.0933, expressed in 721 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79008	2.2319	721

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	87.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	76.90	gold quality
gastrocnemius	UBERON:0001388	76.23	gold quality
muscle of leg	UBERON:0001383	74.53	gold quality
muscle organ	UBERON:0001630	71.34	gold quality
amygdala	UBERON:0001876	69.54	gold quality
cingulate cortex	UBERON:0003027	68.17	gold quality
anterior cingulate cortex	UBERON:0009835	67.96	gold quality
triceps brachii	UBERON:0001509	67.24	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	67.19	gold quality
prefrontal cortex	UBERON:0000451	66.84	gold quality
gluteal muscle	UBERON:0002000	66.81	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	66.50	gold quality
hypothalamus	UBERON:0001898	66.37	gold quality
right frontal lobe	UBERON:0002810	66.27	gold quality
putamen	UBERON:0001874	64.71	gold quality
skeletal muscle tissue	UBERON:0001134	64.37	gold quality
neocortex	UBERON:0001950	64.28	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	64.06	gold quality
spinal cord	UBERON:0002240	64.00	gold quality
frontal cortex	UBERON:0001870	63.82	gold quality
Brodmann (1909) area 9	UBERON:0013540	63.79	gold quality
caudate nucleus	UBERON:0001873	62.99	gold quality
pituitary gland	UBERON:0000007	62.89	gold quality
tibia	UBERON:0000979	62.82	silver quality
cerebral cortex	UBERON:0000956	62.77	gold quality
temporal lobe	UBERON:0001871	62.63	gold quality
forebrain	UBERON:0001890	62.60	gold quality
cortical plate	UBERON:0005343	62.59	gold quality
olfactory bulb	UBERON:0002264	62.58	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.39

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
SPRY4	Repression

miRNA regulators (miRDB)

16 targeting FZD9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-6836-5P	99.60	65.62	1538
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-6876-3P	98.97	65.69	765
HSA-MIR-626	98.89	66.21	762
HSA-MIR-2115-5P	98.66	68.07	1191
HSA-MIR-6823-3P	95.45	66.14	704
HSA-MIR-2114-3P	95.45	66.11	579

Literature-anchored findings (GeneRIF, showing 10)

• transfection of Fzd-9 into a Wnt-7a-insensitive NSCLC cell line established Wnt-7a sensitivity (PMID:15705594)
• ERK5-dependent activation of PPARgamma represents a major effector pathway mediating the anti-tumorigenic effects of Wnt 7a and Fzd 9 in non-small cell lung cancer cells (PMID:16835228)
• Aberrant DNA methylation of frizzled 9 protein is associated with myelodysplastic syndrome progression to acute myeloid leukemia. (PMID:18832655)
• The results suggest that WNT2 could act through its receptor FZD9 to regulate the beta-CATENIN pathway in cumulus cells, recruiting beta-CATENIN into plasma membranes and promoting the formation of adherens junctions involving CDH1. (PMID:19038973)
• SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. (PMID:19724923)
• The presence of nanog, Oct-4, SSEA-1, and SSEA-4 suggests that periodontal ligament mesenchymal stem cells are less differentiated than bone marrow-derived MSCs, and that the frizzled-9/Wnt pathway is important in proliferation and differentiation. (PMID:20458727)
• The activity of the Sprouty4 promoter is increased by Wnt7A/Fzd9 signaling through peroxisome proliferator-activated receptor gamma in lung cancer cells. (PMID:20501643)
• the present study indicated that the methylation profile of the FZD9 gene corresponded to that of a candidate tumorsuppressor gene in acute myeloid leukemia. (PMID:27314612)
• data enforced the evidence that knockdown of c-Fos inhibited cell proliferation, migration, and invasion, and promoted the apoptosis of OS cells accompanied by altered expression of Wnt2 and Fzd9 (PMID:28665975)
• miR-520a-5p regulates Frizzled 9 expression and mediates effects of cigarette smoke and iloprost chemoprevention. (PMID:35149732)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fzd9b	ENSDARG00000014673
danio_rerio	fzd9a	ENSDARG00000035185
mus_musculus	Fzd9	ENSMUSG00000049551
rattus_norvegicus	Fzd9	ENSRNOG00000001452
drosophila_melanogaster	fz3	FBGN0027343

Paralogs (15): FZD3 (ENSG00000104290), SFRP1 (ENSG00000104332), SFRP4 (ENSG00000106483), FZD10 (ENSG00000111432), SFRP5 (ENSG00000120057), SMO (ENSG00000128602), SFRP2 (ENSG00000145423), FZD7 (ENSG00000155760), FZD1 (ENSG00000157240), FRZB (ENSG00000162998), FZD5 (ENSG00000163251), FZD6 (ENSG00000164930), FZD4 (ENSG00000174804), FZD8 (ENSG00000177283), FZD2 (ENSG00000180340)

Protein

Protein identifiers

Frizzled-9 — O00144 (reviewed: O00144)

Alternative names: FzE6

All UniProt accessions (1): O00144

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for WNT2 that is coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. Plays a role in neuromuscular junction (NMJ) assembly by negatively regulating the clustering of acetylcholine receptors (AChR) through the beta-catenin canonical signaling pathway. May play a role in neural progenitor cells (NPCs) viability through the beta-catenin canonical signaling pathway by negatively regulating cell cycle arrest leading to inhibition of neuron apoptotic process. During hippocampal development, regulates neuroblast proliferation and apoptotic cell death. Controls bone formation through non canonical Wnt signaling mediated via ISG15. Positively regulates bone regeneration through non canonical Wnt signaling.

Subcellular location. Cell membrane.

Tissue specificity. Expressed predominantly in adult and fetal brain, testis, eye, skeletal muscle and kidney. Moderately expressed in pancreas, thyroid, adrenal cortex, small intestine and stomach. Detected in fetal liver and kidney. Expressed in neural progenitor cells.

Post-translational modifications. Ubiquitinated by ZNRF3, leading to its degradation by the proteasome.

Domain organisation. Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl (Disheveled) family members and is involved in the activation of the Wnt/beta-catenin signaling pathway. The FZ domain is involved in binding with Wnt ligands.

Miscellaneous. Authors show that FZD9 is responsible for the cellular phenotype found in neural progenitor cells (NPCs) derived from Williams syndrome patients namely increased apoptosis of neural progenitor cells (NPCs).

Similarity. Belongs to the G-protein coupled receptor Fz/Smo family.

RefSeq proteins (1): NP_003499* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000539	Frizzled/Smoothened_7TM	Domain
IPR015526	Frizzled/SFRP	Family
IPR017981	GPCR_2-like_7TM	Domain
IPR020067	Frizzled_dom	Domain
IPR036790	Frizzled_dom_sf	Homologous_superfamily

Pfam: PF01392, PF01534

UniProt features (28 total): topological domain 8, transmembrane region 7, disulfide bond 5, region of interest 2, glycosylation site 2, signal peptide 1, chain 1, domain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00144-F1	81.81	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 39–100, 47–93, 84–122, 111–152, 115–139

Glycosylation sites (2): 53, 158

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-373080	Class B/2 (Secretin family receptors)

MSigDB gene sets: 586 (showing top): GOBP_NEUROMUSCULAR_JUNCTION_DEVELOPMENT, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_MEMBRANE_DEPOLARIZATION, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_COGNITION, GOBP_BEHAVIOR, GOBP_RESPONSE_TO_ELECTRICAL_STIMULUS, GOBP_B_CELL_ACTIVATION, GCANCTGNY_MYOD_Q6, GOBP_NON_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_GROWTH, GOCC_CELL_SURFACE, GOBP_REGENERATION

GO Biological Process (25): ossification (GO:0001503), release of cytochrome c from mitochondria (GO:0001836), nervous system development (GO:0007399), neuroblast proliferation (GO:0007405), learning or memory (GO:0007611), B cell differentiation (GO:0030183), positive regulation of bone mineralization (GO:0030501), non-canonical Wnt signaling pathway (GO:0035567), positive regulation of apoptotic process (GO:0043065), negative regulation of neuron apoptotic process (GO:0043524), regulation of cytosolic calcium ion concentration (GO:0051480), regulation of cell cycle (GO:0051726), negative regulation of mitochondrial depolarization (GO:0051902), canonical Wnt signaling pathway (GO:0060070), negative regulation of necroptotic process (GO:0060546), positive regulation of canonical Wnt signaling pathway (GO:0090263), negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901029), regulation of skeletal muscle acetylcholine-gated channel clustering (GO:1904393), negative regulation of skeletal muscle acetylcholine-gated channel clustering (GO:1904394), bone regeneration (GO:1990523), positive regulation of neural precursor cell proliferation (GO:2000179), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), Wnt signaling pathway (GO:0016055)

GO Molecular Function (7): G protein-coupled receptor activity (GO:0004930), Wnt-protein binding (GO:0017147), protein homodimerization activity (GO:0042803), Wnt receptor activity (GO:0042813), protein heterodimerization activity (GO:0046982), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (10): obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020), filopodium membrane (GO:0031527), mitochondrial membrane (GO:0031966), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR ligand binding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
Wnt signaling pathway	3
skeletal muscle acetylcholine-gated channel clustering	2
transmembrane signaling receptor activity	2
protein dimerization activity	2
organelle membrane	2
cytoplasm	2
multicellular organismal process	1
apoptotic mitochondrial changes	1
apoptotic signaling pathway	1
system development	1
generation of neurons	1
neural precursor cell proliferation	1
behavior	1
cognition	1
lymphocyte differentiation	1
B cell activation	1
bone mineralization	1
regulation of bone mineralization	1
positive regulation of ossification	1
positive regulation of biomineral tissue development	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
negative regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
intracellular calcium ion homeostasis	1
cell cycle	1
regulation of cellular process	1
mitochondrial depolarization	1
regulation of mitochondrial depolarization	1
negative regulation of membrane depolarization	1
regulation of necroptotic process	1
negative regulation of programmed necrotic cell death	1
necroptotic process	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
negative regulation of organelle organization	1

Protein interactions and networks

STRING

1368 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FZD9	WNT5A	P41221	994
FZD9	WNT7A	O00755	955
FZD9	WNT11	O96014	952
FZD9	WNT2	P09544	897
FZD9	CELSR3	Q9NYQ7	858
FZD9	WNT4	P56705	858
FZD9	VANGL2	Q9ULK5	848
FZD9	WNT5B	Q9H1J7	846
FZD9	WNT7B	P56706	832
FZD9	WNT3A	P56704	825
FZD9	FKBP6	O75344	797
FZD9	FKBP10	Q96AY3	788
FZD9	WNT6	Q9Y6F9	787
FZD9	WNT2B	Q93097	777
FZD9	CTNNB1	P35222	773

IntAct

2 interactions, top by confidence:

A	B	Type	Score
FZD9	tcdB	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (6): FZD9 (Two-hybrid), KRTAP10-3 (Two-hybrid), FZD9 (Two-hybrid), TMEM79 (Affinity Capture-Western), FZD9 (Affinity Capture-Western), FZD9 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: B3DIG4, O00144, O57328, O57329, O70421, O75084, O93274, P18537, P23385, P27115, P27808, P41594, P55013, P58421, P97772, Q08463, Q08464, Q13255, Q13467, Q14332, Q24760, Q498S8, Q5BL72, Q5RH73, Q61090, Q61091, Q6NVG7, Q6P9A2, Q6PA90, Q8AVJ9, Q8BKG4, Q8CHL0, Q8IYK4, Q8K4C8, Q9DEB5, Q9EQD0, Q9H461, Q9I9M5, Q9IA02, Q9IA06

Diamond homologs: A0A0K3AWM6, B3DIG4, G5ECQ2, O00144, O19116, O42579, O57328, O57329, O60353, O70421, O75084, O93274, P18537, P58421, P97299, P97401, Q08463, Q08464, Q13467, Q14332, Q24760, Q498S8, Q5BL72, Q5RCN4, Q5RF67, Q5T4F7, Q61086, Q61088, Q61089, Q61090, Q61091, Q6FHJ7, Q7YRN1, Q80YN4, Q863H1, Q8AVJ9, Q8BKG4, Q8C4U3, Q8CHL0, Q8K4C8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FZD9	“down-regulates quantity by repression”	SPRY4	“transcriptional regulation”
FZD9	down-regulates	Proliferation

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	74
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
160898	GRCh38/hg38 7q11.23(chr7:73352304-74719013)x1	Pathogenic

SpliceAI

8 predictions. Top by Δscore:

Variant	Effect	Δscore
7:73434771:T:A	acceptor_gain	0.3400
7:73435285:C:G	acceptor_gain	0.3100
7:73436086:T:TA	acceptor_gain	0.2800
7:73436078:C:CA	acceptor_gain	0.2700
7:73435509:G:GT	donor_gain	0.2300
7:73435482:G:GT	donor_gain	0.2200
7:73435291:CA:C	acceptor_gain	0.2100
7:73435292:AA:A	acceptor_gain	0.2100

AlphaMissense

3807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:73434146:T:A	C47S	1.000
7:73434147:G:C	C47S	1.000
7:73434162:A:G	Y52C	1.000
7:73434234:T:G	F76C	1.000
7:73434276:T:G	F90C	1.000
7:73434279:T:G	F91C	1.000
7:73434284:T:A	C93S	1.000
7:73434285:G:A	C93Y	1.000
7:73434285:G:C	C93S	1.000
7:73434286:C:G	C93W	1.000
7:73434339:G:A	C111Y	1.000
7:73434371:T:A	C122S	1.000
7:73434372:G:C	C122S	1.000
7:73434404:T:A	W133R	1.000
7:73434404:T:C	W133R	1.000
7:73434406:G:C	W133C	1.000
7:73434406:G:T	W133C	1.000
7:73434461:T:A	C152S	1.000
7:73434462:G:C	C152S	1.000
7:73434146:T:C	C47R	0.999
7:73434147:G:A	C47Y	0.999
7:73434148:C:G	C47W	0.999
7:73434161:T:C	Y52H	0.999
7:73434161:T:G	Y52D	0.999
7:73434171:C:T	T55I	0.999
7:73434184:C:A	N59K	0.999
7:73434184:C:G	N59K	0.999
7:73434233:T:C	F76L	0.999
7:73434235:C:A	F76L	0.999
7:73434235:C:G	F76L	0.999

dbSNP variants (sampled 300 via entrez): RS1001342807 (7:73432704 G>A), RS1003019704 (7:73435552 C>A), RS1005658496 (7:73436286 G>A), RS1007825283 (7:73433297 A>G), RS1007903090 (7:73432845 C>A,T), RS1010561681 (7:73432782 A>G), RS1011824273 (7:73435634 C>A,G,T), RS1014068381 (7:73431921 C>T), RS1014743636 (7:73432186 T>C), RS1015078235 (7:73434675 G>A), RS1015566329 (7:73433544 A>G), RS1015831143 (7:73436289 T>A), RS1017877294 (7:73433346 G>A), RS1019557484 (7:73435966 C>A,T), RS1019630729 (7:73435677 C>G,T)

Disease associations

OMIM: gene MIM:601766 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST006119_7	Protein C levels	4.000000e-09
GCST010133_5	Lamb consumption	5.000000e-09
GCST010134_3	Non-oily fish consumption	3.000000e-09
GCST010143_15	Meat-related diet	4.000000e-08
GCST010143_21	Meat-related diet	3.000000e-11
GCST010242_246	HDL cholesterol levels	1.000000e-08
GCST010725_13	Malaria	8.000000e-06
GCST010725_74	Malaria	6.000000e-06
GCST010725_91	Malaria	7.000000e-06
GCST90020026_555	Hip index	4.000000e-10
GCST90020028_163	Hip circumference adjusted for BMI	1.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004633	protein C measurement
EFO:0008111	diet measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523116 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class Frizzled GPCRs

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, affects cotreatment	2
FR900359	decreases phosphorylation	1
terbufos	increases methylation	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	decreases expression	1
perfluorooctanoic acid	decreases expression	1
evodiamine	increases expression	1
2-palmitoylglycerol	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
(+)-JQ1 compound	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	affects expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1
Estradiol	increases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Niclosamide	decreases expression	1
Parathion	increases methylation	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Mifepristone	increases expression	1
Cadmium Chloride	decreases expression	1
Acrylamide	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4376177	Binding	Binding affinity to Frizzled-9 CRD (unknown origin)	Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate Clostridium difficile Toxin B Pathogenicity in Epithelial Cells. — J Med Chem

Cellosaurus cell lines

7 cell lines: 6 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7QC	Ubigene A-549 FZD9 KO	Cancer cell line	Male
CVCL_D9F8	Ubigene HEK293 FZD9 KO	Transformed cell line	Female
CVCL_SP25	HAP1 FZD9 (-) 1	Cancer cell line	Male
CVCL_SP26	HAP1 FZD9 (-) 2	Cancer cell line	Male
CVCL_SP27	HAP1 FZD9 (-) 3	Cancer cell line	Male
CVCL_SP28	HAP1 FZD9 (-) 4	Cancer cell line	Male
CVCL_SP29	HAP1 FZD9 (-) 5	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.